Literature DB >> 21949914

Anaemia is of prognostic significance in patients with oesophageal adenocarcinoma.

I Tanswell1, H Steed, J Butterworth, G Townson.   

Abstract

Anaemia is common in a wide range of malignancies and individual studies have demonstrated it to be an independent prognostic marker for survival in certain cancer types. The study population consisted of 171 patients: 77 anaemic and 94 non-anaemic. Sixty per cent of the study population had adenocarcinoma with 37% having squamous cell carcinoma. Late-stage disease occurred in 80% of individuals. There was no significant difference in survival times between the two groups (p=0.1), and after adjusting for confounding factors including age, sex, stage and physical status (p=0.8). Anaemic individuals with adenocarcinoma suffered a poorer survival probability compared to those with normal haemoglobon level (p=0.02). Anaemia is common at diagnosis in oesophageal cancer and was found to be a significant prognostic indicator of survival in adenocarcinoma, but not squamous cell carcinoma.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21949914     DOI: 10.4997/JRCPE.2011.304

Source DB:  PubMed          Journal:  J R Coll Physicians Edinb        ISSN: 1478-2715


  3 in total

1.  Iron chelation: a potential therapeutic strategy in oesophageal cancer.

Authors:  B D Keeler; M J Brookes
Journal:  Br J Pharmacol       Date:  2013-03       Impact factor: 8.739

2.  A comparative study of the iron status of patients with oesophageal adenocarcinoma to determine suitability for a clinical trial of iron chelation therapy.

Authors:  S J Ford; M R Bedford; W Pang; A Wood; T Iqbal; C Tselepis; O Tucker
Journal:  Ann R Coll Surg Engl       Date:  2014-05       Impact factor: 1.891

3.  Deferasirox (ICL670A) effectively inhibits oesophageal cancer growth in vitro and in vivo.

Authors:  S J Ford; P Obeidy; D B Lovejoy; M Bedford; L Nichols; C Chadwick; O Tucker; G Y L Lui; D S Kalinowski; P J Jansson; T H Iqbal; D Alderson; D R Richardson; C Tselepis
Journal:  Br J Pharmacol       Date:  2013-03       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.